Medically reviewed by Gagandeep Brar, MD Stage 1 and 2 prostate cancer stays in your prostate, and the five-year survival ...

About 1 in 8 men will be diagnosed with prostate cancer in their lifetime The average age at diagnosis is 67 Less than 1% of the 3.5 million men living with prostate cancer are expected to die from it ...

Moving Beyond Imaging in metastatic castration-resistant prostate cancer: Liquid biopsy cfNA profiling of PTEN-FANCD2-POLQ as molecular signatures of response to 177Lu-PSMA-617. This is an ASCO ...

Truqap extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer compared to placebo, with a median rPFS of 33.2 months. Truqap was associated with higher rates of ...

In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...

Medically reviewed by Gagandeep Brar, MD End-stage prostate cancer can cause urinary symptoms, including blood in your urine ...

The goal of most anti-cancer approaches, including chemotherapy, radiation, immunotherapies, targeted therapies, and bone ...

The 8-year overall survival rate was 78.9% with enzalutamide-leuprolide and 69.5% with leuprolide alone. Treatment with enzalutamide plus leuprolide reduces the risk of death by more than 40% in ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer. Adding the drug enzalutamide to standard hormone therapy reduced the risk of ...